

FY 2007 Business Results

(Year ended March 31, 2008)

¥mn

	Actual						Forecast			
	2006		2007		YOY		2008		YOY	
	Amount	Distrib.	Amount	Distrib.	Amount	%	Amount	Distrib.	Amount	%
Consolidated Sales		%		%				%		%
Pharmaceuticals	19,072	91.0	19,823	94.8	750	3.9	23,000	96.2	3,177	16.0
Nursing homes	758	3.6	—	—	(758)	—	—	—	—	—
Othres	1,135	5.4	1,095	5.2	(40)	(3.5)	900	3.8	(195)	(17.8)
Total sales	20,966	100.0	20,918	100.0	(47)	(0.2)	23,900	100.0	2,982	14.3
Welllife sales	758		—		(758)					
Excluding Welllife	20,208		20,918		710	3.5	23,900		2,982	14.3
Income & Losses										
Cost of sales	8,682	41.4	8,780	42.0	98	1.1				
YOY(%)						0.6P				
SG&A expenses	10,888	51.9	10,967	52.4	78	0.7				
Operating income	1,395	6.7	1,170	5.6	(224)	(16.1)	1,400	5.9	230	19.6
Welllife income	202		—		(202)		—		—	
Excluding Welllife	1,192		1,170		(22)	(1.8)	1,400	5.9	230	19.6
Non-operating Income & losses	(251)		(162)		89	35.5				
Ordinary income	1,143	5.5	1,008	4.8	(135)	(11.9)	1,200	5.0	192	19.0
Extraordinary Income & losses	(197)		(90)		106					
Income tax: current	894		363		(530)					
Income tax: deferred	(313)		163		476	—				
Minority interests	—		—		—	—	—		—	—
Net income	366	1.7	390	1.9	24	6.6	600	2.5	210	53.8
Non-consolidated Sales										
Uralyt	3,083		3,474		391	12.7	3,650			
Soleton	4,097		3,957		(140)	(3.4)	3,750			
Calvan	779		724		(55)	(7.1)	700			
Core products	7,959	46.9	8,155	45.7	196	2.5	8,100	38.4	(55)	(0.7)
Pravastan	1,203		1,224		21	1.7	1,300			
Vogseal	445		559		114	25.6	800			
Others	7,365		7,897		532	7.2	10,900			
Generics	9,013	53.1	9,680	54.3	667	7.4	13,000	61.6	3,320	34.3
Total	16,972	100.0	17,835	100.0	863	5.1	21,100	100.0	3,265	18.3
Consolidated										
R&D expenses	1,464	7.0	1,317	6.3	(147)	(10.0)	1,380	5.8	62	4.8
Depreciation expenses	253	1.2	282	1.4	29	11.5	601	2.5	318	112.4
Capital expenditure	175	0.8	1,116	6.3	941	6.4 times	1,015	4.2	(101)	(9.1)